What are the short-term technical indicators suggesting for RNA?

The short-term technical indicators for Avidity Biosciences (RNA) are not currently available. However, it is important to note that the company's stock performance can be analyzed using various technical indicators such as moving averages, MACD, RSI, and BOLL.

1. **Moving Averages**: The 5-Day, 10-Day, and 20-Day Moving Averages are not currently available. These indicators smooth out price data by using an average of a specified number of recent data points. A bullish signal is typically generated when the price crosses above the moving average, while a bearish signal is indicated by a cross below.
2. **MACD (Moving Average Convergence Divergence)**: The MACD indicator is not available. This tool calculates the difference between two moving averages of a stock's price. The MACD line is then plotted along with a signal line, which is typically a moving average of the MACD. A bullish trend is indicated when the MACD line crosses above the signal line, while a bearish trend is suggested by a cross below.
3. **RSI (Relative Strength Index)**: The RSI indicator is not available. This tool measures the speed and change of price movements. It helps identify overbought or oversold conditions in a market. An RSI below 30 is generally considered oversold, indicating a stock may be undervalued and due for a price increase. Conversely, an RSI above 70 is considered overbought, suggesting that a stock may be overvalued and due for a price correction.
4. **BOLL (Bollinger Bands)**: The BOLL indicator is not available. This tool consists of an upper value, a mid value (based on a moving average), and a lower value. The BOLL indicator can be used to identify volatility in a market. When the price moves outside the upper or lower value, it is considered an outlier, which may indicate a potential trend reversal.

Given the unavailability of these indicators, it is recommended to rely on fundamental analysis, market news, and other technical indicators to make informed decisions about RNA's stock performance.